STERLING's INOCOR (AMRINONE) I.V. IS "APPROVABLE" the company announced in a May 23 press release. The drug will be marketed to U.S. physicians and hospitals by Sterling's Winthrop-Breon Labs pending FDA approval of labeling and packaging information. Sterling said that Inocor I.V. will be used in hospitals among patients with severe congestive heart failure unresponsive to other therapies. The release describes amrinone as an "inotropic agent which improves directly the pumping force of the heart and serves simultaneously as a mild dilator of the blood vessels." The approval of the I.V. form of amrinone follows in the wake of Sterling's decision in January to halt clinical studies on the oral form of the drug because of a high incidence of gastro-intestinal side effects (The Pink Sheet" Jan. 23, T&G-2). In October 1982, FDA's Cardio-Renal Drugs Advisory Cmte. declined to recommend approval of oral amrinone until Sterling completed an additional long-term clinical study. However, after preliminary review of the study showed that the high incidence of gastrointestinal side effects was causing a drop out rate that would make it difficult to establish statistical significance of efficacy, Sterling made the decision to halt work on the oral drug. The company has not withdrawn its pending NDA from FDA on that form, however. Along with the announcement in January of its decision to halt the clinical study with oral amrinone, Sterling said that it intended to "accelerate both oral and intravenous studies on milrinone," an analogue of amrinone also for the treatment of congestive heart failure. Sterling noted that preliminary clinical studies have show that milrinone "is 10 to 30 times more potent than amrionone, Sterling's first inotropic discovery, and has been remarkably free of side effects." The company said that milrinone "has entered expanded clinical trials for both oral and intravenous dosage forms. Results with both forms appear encouraging."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.
Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.
Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.
